R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

Juan Montoro, Giovanna Andreola, Angelo Gardellini, Aleksandra Babic, Mara Negri, Niccolò Frungillo, Giovanni Martinelli, Daniele Laszlo

Research output: Contribution to journalArticlepeer-review

Abstract

Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×106 CD34+cells/kg, 80% of them at least 5×106 CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.

Original languageEnglish
Pages (from-to)411-414
Number of pages4
JournalTransfusion and Apheresis Science
Volume50
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • CD34+ collection
  • Diffuse large B-cell lymphoma
  • Pegfilgrastim
  • R-ESHAP
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this